GSK’s Prices Breo On Par With Advair For COPD
This article was originally published in The Pink Sheet Daily
Executive Summary
The wholesale acquisition cost of GlaxoSmithKline’s once-daily COPD medication Breo is the same as Advair, reflecting the high reimbursement hurdle for new respiratory medicines.